Dean Calhoun, Affygility Solutions - Qepler Summits And Conferences

Dean Calhoun

Affygility Solutions
Denver, USA
Providing EHS compliance management software, potent compound safety, control banding, occupational toxicology, industrial hygiene services to the life sciences industry.

Dean Calhoun is an American Board of Industrial Hygiene Certified Industrial Hygienist (CIH). He has been an environmental health and safety professional for over 33 years.

Prior to starting Affygility Solutions, Dean was the Associate Director of Environmental Health and Safety for Gilead Sciences, Inc., a biopharmaceutical company focused on developing pharmaceuticals for infectious, viral, and oncology applications. His experiences including development and implementation of global EHS guidelines, implementation and coordination of an executive management EHS Steering Committee, establishment of occupational exposure limits for pharmaceutical active ingredients, industrial hygiene program management, and EH&S auditing of research, manufacturing and contract manufacturing facilities.

Dean is an international speaker on the topic of potent compound safety and has presented at conferences throughout the United States, Europe, and Asia.

Dean graduated with a B.Sc. degree in Engineering from the University of Wyoming and has dual master degrees in Environmental Policy and Management, and Technology Management from the University of Denver. He is a member of AIHA, ISPE, and NAEM.

Related Sessions:

Highly Potent APIs
Summit 2019

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 20 Feb 2019
  • Berlin, DE
  • Pharma
Day 2: Thursday, 21 February 2019
CASE STUDY: Top ten audit findings from HPAPI facilities.

In order to have an effective potent compound safety program, auditing must be performed on a periodic basis. In this session, Dean Calhoun will share the top ten audit findings based decades of professional auditing experience throughout the world.

View Details

2nd Annual Highly Potent APIs
Summit 2020

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 19 Feb 2020
  • Prague, CZ
  • Pharma
Day 1: Wednesday, 19 February 2020
CASE STUDY: Health Based Exposure Limits 2020: Do we have 2020 vision now?

In this 20-minute presentation, Dean Calhoun, President and CEO of Affygility Solutions will discuss the brief history of health based exposure limits since its June 2015 effective team; common challenges and misunderstandings regarding HBELs; and future trends and where we are heading with HBELs.

View Details

4th Annual Highly Potent
APIs Summit 2024

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 21 Feb 2024
  • Virtual,
  • Pharma
Day 1: Wednesday, 21 February 2024
CASE STUDY: AI advancements in HPAPI CDMO industry

Artificial intelligence (AI) is revolutionizing the HPAPI CDMO industry by enhancing drug discovery and development processes, improving manufacturing efficiency and quality control, optimizing supply chain management, and enabling improvements in the categorizations of HPAPIs. AI algorithms and machine learning techniques are now being employed to analyze vast amounts of compound data and make data-driven decisions regarding the classification of compounds and the setting of robust OELs and ADEs. The impact of AI on the HPAPI CDMO industry is expected to grow in the coming years, as AI continues to evolve and become more sophisticated.

This will lead to even more innovation, efficiency, and quality in the development and manufacturing of HPAPI drugs. In this presentation, we will discuss the following:

  • The basics of AI
  • AI tools currently being used in the pharmaceutical industry
  • A novel database of OELs/ADEs and how AI will be used to improve decisions regarding HPAPI compound categorization
View Details